The global newborn screening market will reach 1.43 billion US dollars in 2022

Source: Bio exploration 2015-09-21 industry analysis according to the latest report of grand view research, the global newborn screening market scale in 2014 was $640.5 million, which is expected to reach $1.43 billion in 2022 The increasing cases of neonatal congenital diseases and the increasing demand for neonatal screening have promoted the development of the whole market The innovation of technology, the research on the effectiveness of new therapies, and the government's support for the diagnosis of diseases (such as PKU, GS, CH, and hearing impairment of newborn) play an important role in the development of the market The improvement of public awareness is another important factor to promote the development of newborn market The United States Triangle Institute (RTI), the Centers for Disease Control and prevention, and the National Center for birth defects and developmental disorders worked together to further develop research projects to enhance the practical awareness of neonatal screening The Indian Public Health Foundation estimates that more than 400 million infants worldwide are affected by metabolic diseases such as glucose-6-phosphate dehydrogenase deficiency (G6PD) According to CDC statistics, more than 4 million newborns are screened for metabolic disorders every year in 50 states of the United States In recent years, the state-run newborn screening program has greatly improved the medical status of children in the United States Screening technology analysis advanced technology as a diagnostic tool to improve the probability of neonatal screening Neonatal screening techniques include tandem mass spectrometry, blood oxygen determination, enzyme level determination, DNA analysis and electrophoresis In the 1990s, the use of mass spectrometry made it possible to screen many conditions, and the technology helped to identify amino acids and other compounds Nowadays, the market analysis shows that tandem mass spectrometry is the technology field with the largest market share of neonatal screening, with an annual compound growth rate of 11.1% DNA analysis is one of the main techniques in neonatal screening Experts believe it will change the pattern of screening from identifying a disease with one test to identifying multiple conditions at once From the perspective of market analysis, the application of DNA analysis technology in neonatal screening is increasing gradually It is expected that in 2022, the application of DNA analysis technology in neonatal screening market will double The dry blood spot test accounted for 45% of the total newborn screening market revenue Free blood spot collection cards are available in North America to expand the entire screening market Severe congenital heart disease (CCHD) is a common disease, which is currently screened by blood oxygen measurement It is estimated that 18 out of 10000 infants have severe congenital heart disease, which, if not screened, could lead to death, and the screening market for the disease is expected to grow significantly in the next seven years Regional analysis is the leading market in North America because of the increasing incidence rate of cardiovascular diseases However, there are a large number of newborns affected by metabolic diseases in the world, especially in Africa, the Middle East and subtropical regions Therefore, the growth rate of neonatal screening market in Asia Pacific region is the fastest in the forecast period, which will exceed 11.0% Especially in the past few years, the awareness and quality assurance of newborn screening in South Korea, China, India and Sri Lanka have been increasing This growth is due to a large number of undeveloped opportunities, rising medical funding, increased disease prevalence and government support Market competition analysis some of the major manufacturers in the neonatal screening market include Agilent Technologies, absciex, natus medical, PerkinElmer, Covidien, Masimo, trivitron medical, bio rad, GE Medical and waters The active participation and strategic cooperation of businesses ensure the sustainability of the market For example, trivitron medical and Agilent Technology Co., Ltd launched the field of high-precision in vitro diagnosis based on LC-MS / MS platform Newborn screening has also brought huge benefits to these enterprises According to analysts' analysis, Perkin Elmer's newborn screening business will generate $250-350 million in revenue due to the increase of birth rate, expansion of testing menu and geographical expansion in the United States, accounting for 65-70% of the newborn screening market in the United States.